***Method Article for Study Protocol***

***Manuscript Title***

First Name(s) Surnamea, First Name(s) Surnamea, First Name(s) Surnameb, First Name(s) Surnamec, First Name(s) Surnamea

a Department, Institute/University/Hospital, City, (State,) Country

b Department, Institute/University/Hospital, City, (State,) Country

c Department, Institute/University/Hospital, City, (State,) Country

Short Title: to be used as running head

Corresponding Author:

Full name

Department

Institute/University/Hospital

Street Name & Number

City, State, Postal code, Country

Tel:

E-mail:

Number of Tables: Please indicate the number of tables submitted.

Number of Figures: Please indicate the number of figures submitted.

Word count: Please indicate the word count including Abstract and body text. This is not to include the title page, reference list or figure legends.

Keywords: Please provide 3–5 keywords highlighting the most important points of your paper.

**Abstract**

A short Abstract should summarize the main points and reflect the content of the article. It should be written in a clear and concise way and be structured using the following subheadings: Introduction, Methods/Design and Discussion/Conclusion. Abbreviations used in the main text may be introduced and used. Use neither bibliographic references nor references to figures or tables in the Abstract. Clinical trial study protocols must be pre-registered and the trial/study registration number should be provided here where applicable.

Please refer to the Author Guidelines for more information about the maximum accepted word count of the Abstract in your chosen journal. Where no specific word count is provided, an abstract of between 200-400 words is permitted. **Introduction**

The Introduction should provide a summary of the background literature and rationale for the study and the study’s primary, and any secondary, objectives. If relevant for the study, the clinical trial study design should be specified here.

**Methods/Design**

The Methods/Design section should provide a detailed description of all steps of study protocol, including, where applicable, recruitment strategy and timeline, intervention, allocation and masking, outcome measures and data collection, and analysis plans. Methods/Design sections must adhere to the relevant reporting guidelines for their study design, such [SPIRIT](https://www.spirit-statement.org/) , [PRISMA-P](https://prisma-statement.org/Extensions/Protocols) or other relevant reporting guidelines as detailed on the [Equator Network website](https://www.equator-network.org/reporting-guidelines/).

**Discussion/Conclusion**

The Discussion/Conclusion should provide an evaluation of the research plan, implications of this research for the broader field, detail of the dissemination plan for the research and discussion of any limitations or potential obstacles. Discussion of any other subjects that are not covered in the sections above should be included here.

**Statements**

All papers must contain the following statements after the main body of the text and before the reference list:

**A****cknowledgement (optional)**

In the Acknowledgement section, authors must include individuals and organizations that have made substantive contributions to the research or the manuscript. An exception is where funding was provided, which should be included in Funding Sources. Please refer to the Guidelines issued by the [ICMJE](http://www.icmje.org/) to determine non-author contributors that should be included in the Acknowledgement section.

###### Statement of Ethics

Published research must comply with the guidelines for human studies and should include evidence that the research was conducted ethically in accordance with the [World Medical Association Declaration of Helsinki](https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.wma.net%2Fpolicies-post%2Fwma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects%2F&data=04%7C01%7Ck.fava%40karger.com%7Cff60788f01494d8ede1508d90a2bbe0c%7C69e7eb606e904a0590b15b8d6d697087%7C0%7C0%7C637552005543134106%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=nSOENd4lDTmaY0rkWNEYSLf%2BelqKO0wq%2FL1kkSVIvnU%3D&reserved=0). In the manuscript, authors should state that subjects  have given their written informed consent and that the study protocol was approved by the institute’s committee on human research. If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should be detailed in the manuscript. Studies involving animals must have been approved by the authors' Institutional Animal Care and Use Committee (IACUC) or equivalent ethics committee and must follow internationally recognized guidelines such as the [ARRIVE guidelines](https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.nc3rs.org.uk%2Farrive-guidelines&data=04%7C01%7Ck.fava%40karger.com%7Cff60788f01494d8ede1508d90a2bbe0c%7C69e7eb606e904a0590b15b8d6d697087%7C0%7C0%7C637552005543134106%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=fm5UN7Ia%2BwxCFpUMBxyD3Wg2dw71mGduYo%2FyHaHWYms%3D&reserved=0). Please address the following aspects in your Statement of Ethics.

Study approval statement: Provide name and affiliation of the committee who approved the study and the decision reference number. An example statement can be found here: "*This study protocol was reviewed and approved by [committee name and affiliation], approval number [XXX]*." If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be stated, including the name of the ethics committee who made that decision.

Consent to participate statement: For studies using human participants, state whether written informed consent was obtained from participants (or their parent/legal guardian/next of kin) to participate in the study. If written informed consent was not required, or if the study has been granted an exemption from requiring written informed consent, this should also be stated, including the name of the ethics committee who made that decision.

###### Conflict of Interest Statement

Authors are required to disclose any possible conflicts of interest. All forms of support and financial involvement (e.g. employment, consultancies, honoraria, stock ownership and options, expert testimony, grants or patents received or pending, royalties) which took place in the previous three years should be listed, regardless of their potential relevance to the paper. Also the nonfinancial relationships (personal, political, or professional) that may potentially influence the writing of the manuscript should be declared. If there is no conflict of interest, please state: “The authors have no conflicts of interest to declare.”

###### Funding Sources

Authors must give full details about the funding of any research relevant to their study, including sponsor names and explanations of the roles of these sources in the preparation of data or the manuscript.

###### Author Contributions

In the Author Contributions section, a short statement detailing the contributions of each person named as an author should be included. Contributors to the paper who do not fulfil the [ICMJE Criteria for Authorship](https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.icmje.org%2Frecommendations%2Fbrowse%2Froles-and-responsibilities%2Fdefining-the-role-of-authors-and-contributors.html&data=04%7C01%7Ck.fava%40karger.com%7Cff60788f01494d8ede1508d90a2bbe0c%7C69e7eb606e904a0590b15b8d6d697087%7C0%7C0%7C637552005543144066%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=QBfoT6JcFIpswsIllt2YnvL4fkIMHENDcVTlHkfgnPI%3D&reserved=0" \t "_blank" \o "Ursprüngliche URL: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html. Klicken oder tippen Sie, wenn Sie diesem Link Vertrauen.) should be credited in the Acknowledgement section.

If an author is removed from or added to the listed authors after submission, an explanation and a signed statement of agreement confirming the requested change are required from all the initially listed authors and from the author to be removed or added.

**Data Availability Statement**

Authors are required to provide a Data Availability Statement in their article that details whether data are available and where they can be found. The journal’s data sharing policy strongly encourages authors to make all datasets on which the conclusions of the paper rely available to editors, reviewers and readers without unnecessary restriction wherever possible. In cases where research data are not publicly available on legal or ethical grounds, this should be clearly stated in the Data Availability Statement along with any conditions for accessing the data. Examples of Data Availability Statements and additional information on the data sharing policy can be found on the journal homepage under “Guidelines”.

**References [Alphabetical]**

The list of references should include only those publications which are cited in the text, in alphabetical order. Material submitted for publication but not yet accepted may be cited in the text as “unpublished data” but must not be included in the reference list. The author’s surname should be followed by their initials with no punctuation other than a comma to separate individual authors. If there are more than 6 authors, cite 5 authors followed by “et al.”

In-text citations should be structured as follows:  
Single author: Jones [1999]  
Two authors: Jones and Smith [2000]  
More than two authors: Jones et al. [2001]

More information on good referencing practice, as well as further examples, can be found in [The National Library of Medicine Style Guide for Authors](https://www.ncbi.nlm.nih.gov/books/NBK7256/).

Examples

Papers published in journals:

Sawant KV, Xu R, Cox R, Hawkins H, Sbrana E, et al: Chemokine CXCL1-mediated neutrophil trafficking in the lung: role of CXCR2 activation. J Innate Immun 6:647–658 (2015).

(Journal names should be abbreviated according to the Index Medicus.)

Papers published only with DOI number:

Chen C, Hu Z: ApoE polymorphisms and the risk of different subtypes of stroke in the Chinese population: a comprehensive meta-analysis. Cerebrovasc Dis DOI: 10.1159/000442678.

Monographs:

Matthews DE, Farewell VT: Using and Understanding Medical Statistics. 5th ed, revised (Karger, Basel 2015).

Edited Books:

Cohen SR, Gardner TW: Diabetic retinopathy and diabetic macular edema, in Nguyen QD, Rodrigues EB, Farah ME, Mieler WF, Do DV (eds): Retinal Pharmacotherapeutics. Dev Ophthalmol, vol 55, pp 137–146 (Karger, Basel 2016).

Websites:

Driscoll DJ, Miller JL, Schwartz S, Cassidy SB: Prader-Willi syndrome, in Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, et al (eds): GeneReviews® [Internet] (University of Washington, Seattle 1993–2017). Initial posting: October 6, 1998; last update: February 4, 2017.

(To be cited in text as 2017.)

Rambaut A, Suchard MA, Xie D, Drummond AJ: Tracer v1.6. Available from <http://beast.bio.ed.ac.uk/Tracer> (2014).

**Figure Legends**

Fig. 1. Legend text.

Fig. 2. Legend text.

Figures should be mentioned in the manuscript text as follows:   
Without round brackets:

“…shown in Figure 1…” or “…shown in Figures 1 and 4…” or “…shown in Figures 2–6…” always with capital letters and written out.

With round brackets:

“(shown in Fig. 1)” or “(shown in Fig. 1, 4)” or “(shown in Fig. 2–6)”, always abbreviated as “Fig.” followed by the number or numbers after a full stop and a space.

In the Legend:

“Fig. 1.” or “Fig. 1. a”, always abbreviated as “Fig.” followed by the number after a full stop and a space

Please note that the actual figures and all tables should be uploaded as separate items in their original file format.